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Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) is a major cause of serious hospital-acquired infections
and is responsible for significant morbidity and mortality in residential care facilities. New agents against
MRSA are needed to combat rising resistance to current antibiotics. We recently reported
5-hydroxy-3-methyl-1-phenyl-1H-pyrazole-4-carbodithioate (HMPC) as a new bacteriostatic agent against
MRSA that appears to act via a novel mechanism. Here, twenty nine analogs of HMPC were synthesized, their
anti-MRSA structure-activity relationships evaluated and selectivity versus human HKC-8 cells determined.
Minimum inhibitory concentrations (MIC) ranged from 0.5 to 64 μg/mL and up to 16-fold selectivity was
achieved. The 4-carbodithioate function was found to be essential for activity but non-specific reactivity was
ruled out as a contributor to antibacterial action. The study supports further work aimed at elucidating the
molecular targets of this interesting new class of anti-MRSA agents.
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Methicillin-resistant Staphylococcus aureus (MRSA) is a major cause of serious hospital-
acquired infections and is responsible for significant morbidity and mortality in residential 
care facilities. New agents against MRSA are needed to combat rising resistance to current 
antibiotics. We recently reported 5-hydroxy-3-methyl-1-phenyl-1H-pyrazole-4-carbodithioate 
(HMPC) as a new bacteriostatic agent against MRSA that appears to act via a novel 
mechanism. Here, twenty nine analogs of HMPC were synthesized, their anti-MRSA 
structure-activity relationships evaluated and selectivity versus human HKC-8 cells 
determined. Minimum inhibitory concentrations (MIC) ranged from 0.5−64 µg/mL and up to 
16-fold selectivity was achieved. The 4-carbodithioate function was found to be essential for 
activity but non-specific reactivity was ruled out as a contributor to antibacterial action. The 
study supports further work aimed at elucidating the molecular targets of this interesting new 
class of anti-MRSA agents.  
  
Methicillin-resistant Staphylococcus aureus (MRSA) is the most common cause of hospital-
acquired infections
1,2
 and a frequent source of skin and soft tissue infections in the North and 
Latin Americas, Europe and Asia.
3,4
 In the USA, MRSA accounts for almost 60% of clinical 
S. aureus strains isolated from intensive care units
5
 and it is widespread in residential care 
facilities.
6,7 
Worryingly, pathogenic strains are also becoming more prevalent in the 
community (i.e. community-acquired MRSA).
8
 Vancomycin has been used extensively for 
several decades to treat complicated S. aureus and other Gram-positive infections. However, 
concerns have been growing over the increasing minimum inhibitory concentration (MIC) of 
the drug against MRSA isolates,
9
 and its use has other well-known shortcomings (e.g. 
nephrotoxicity, complex pharmacokinetics, requirement for slow intravenous infusion).
10
  
It is evident that vancomycin’s effectiveness will continue to wane in the coming 
years, thus compelling the discovery of effective new antibiotics against this major human 
pathogen. 
We recently reported the discovery of 5-hydroxy-3-methyl-1-phenyl-1H-pyrazole-4-
carbodithioate (HMPC) 1 (Scheme 1) as a new bacteriostatic agent against MRSA.
11
 The 
compound showed the same minimum inhibitory concentration (MIC 4 µg/mL) against 
MRSA MW2 (lab strain) and six recent clinical isolates and was able to rescue 
Caenorhabditis elegans from an MRSA infection. Whole-genome sequencing of mutants 
resistant to 1 highlighted a role for the global defense regulator MgrA
12
 in its mechanism and 
the compound displayed a S. aureus promoter-lux array luminescence profile distinct from all 
major classes of antibiotics. HMPC 1 appears to exert anti-staphylococcal effects through a 
novel, uncharacterized mechanism that involves an MgrA-mediated defense response.
 
In the 
current report, we explored the structural requirements for anti-MRSA activity and eukaryotic 
cell selectivity in the pyrazole-4-carbodithioate class. 
Initial efforts sought to understand the role of the 4-carbodithioate by replacing the 
group with amide 2, thioamide 3 and ester 5 isosteres (Scheme 1). Analogs 2 and 3 were 
formed by quenching the enolate of pyrazolin-3-one 7 (generated using K2CO3) with n-propyl 
isocyanate and n-propyl isothiocyanate, respectively. Ester 5 was obtained by first generating 
ketene dithioacetal 4 from 7 using K2CO3, CS2 and excess CH3I via the reported method.
13
 
Subsequent reaction of 4 with sodium in n-PrOH at 80 °C delivered 5. Compounds 2, 3, 5 
and intermediate 4 all showed no activity against MRSA MW2 (MIC > 64 µg/mL), 
establishing the critical importance of the 4-carbodithioate function. 
 The role of the neighboring 3-OH substituent was investigated next but attempting to 
prepare the O-Me ether of 1 by treatment with K2CO3 and excess CH3I instead delivered 
ketene dithioacetal 6 (44% yield). Compound 6 was also found to be inactive against MRSA 
(MIC > 128 µg/mL). 
 
 
Scheme 1. Reagents and conditions: a. K2CO3, n-propyl isocyanate, DMF/benzene, rt, 56%; 
b. K2CO3, n-propyl isothiocyanate, DMF/benzene, 50 °C, 80% c. K2CO3, CS2, CH3I, 
DMF/benzene, 0 °C, 66%; d. n-BuLi, CS2, n-bromopropane, THF, 0-25 °C, 52%,
14
 e. Na(s), 
n-PrOH, 80 °C, 91%;
15
 f. K2CO3, CH3I, DMF 0-25 °C, 90%. 
 
Replacement of the carbodithioate n-propyl chain with Me, Et, allyl, n-Bu, Bn and 3-
pyridyl groups was explored next. Each of these was obtained by forming the enolate of 7 
with n-butyllithium and successively quenching with CS2 and the appropriate alkyl halide 
(Figure 1(a)). Shortening the chain to one carbon 8a led to a 4-fold drop in potency, while Et 
derivative 8b produced a 2-fold loss. Introduction of an alkene 8c maintained or slightly 
reduced potency and extension by 1 carbon 8d increased potency 2-fold. Addition of steric 
bulk and hydrophobicity with a benzyl group 8e resulted in a 2-fold increase in activity, but a 
significant drop in potency occurred when a nitrogen atom was introduced into the benzylic 
substituent 8f (MIC 16-32 mg/mL, Figure 1(b)). 
In our previous report,
11
 we showed that HMPC 1 does not cause hemolysis of human 
red blood cells at concentrations up to 64 µg/mL but is cytotoxic towards eukaryotic HKC-8 
and HepG2 cells at concentrations around its MRSA MIC. Here, cytotoxicity of analogs 8a-e 
was tested in HKC-8 cells and selectivity indices were calculated (SI = HKC-8 IC50/MRSA-
MW2 MIC, Figure 1(b)). No MRSA selectivity was observed for 8a, 8b or 8d and modest 
selectivity (2-4 fold) was seen with allyl derivative 8c. Benzylic derivative 8e delivered the 
highest selectivity (8-16 fold) in this series. 
A variety of halo, electron donating and electron withdrawing substituents were added 
to the 4-position of the pyrazole N-phenyl group. Commercially available 4-substituted 
phenylhydrazine.HCl salts 9a-g were condensed with ethyl acetoacetate to form pyrazol-3-
one intermediates 10a-g in 25-87% yield. Treating ketones 10a-g with n-butyllithium and 
quenching the enolates with CS2 followed by n-bromopropane gave targets 11a-g in 32-75% 
yield (Figure 1(a)). 
Addition of a Me group 11a gave no change in activity (relative to 1) while 
introducing an electron donating methoxy group 11b produced a 2-fold loss. Halogen 
substituents 11c-e gave slight increases in potency (2-4 fold), as did electron withdrawing 
cyano and nitro groups, with the  p-NO2-substituted analog 11g showing the highest activity 
(MIC 0.5-1 µg/mL). Corresponding increases in eukaryotic cell cytotoxicity were observed 








































































































































Figure 1. (a) Synthesis of pyrazole-4-carbodithioate analogs. Reagents and conditions: a. n-
BuLi, CS2, alkyl halide, THF, 0-25 °C, 59-84%; b. glacial acetic acid, EtOH, 45-50 °C, 19-
90%; c. n-BuLi, CS2, n-bromopropane, THF, 0-25 °C. (b) Antibacterial activities (MIC 
µg/mL) against MRSA-MW2, cytotoxicity towards HKC-8 cells (IC50 µg/mL) and selectivity 
indices (SI). 
 
Replacement of the 3-methyl group of 1 with a phenyl ring was explored next. 
Condensation of phenylhydrazine.HCl with ethyl benzoylacetate 12a produced pyrazol-3-one 
13a, which upon base treatment and successive quenching with CS2 and n-bromopropane 
afforded 3-phenyl derivative 14a in 90% yield. Compound 14a showed a 2-fold increase in 
MRSA potency and a 16-fold increase in selectivity. The promising selectivity obtained upon 
addition of the phenyl ring at the 3-position led to exploration of para-substituted analogs 
carrying halo, electron donating and electron withdrawing substituents. Condensation of p-
substituted ethylbenzoylacetates 12b-i with phenylhydrazine.HCl and appending n-propyl 
dithioate groups to the resulting ketones 13b-i delivered target analogs 14b-i. Addition of the 
Me group 14b led to a slight increase in potency (MIC 1-2 µg/mL) relative to 1 but reduced 
selectivity. The methoxy group 14c did not change activity against MRSA but selectivity was 
reduced. Larger increases in antibacterial potency were achieved with halo groups 14d-f 
(MIC 0.5-1 µg/mL) but no improvements in selectivity were seen. A large drop in potency 
was observed with the CF3 group 14g (MIC 32-64 mg/mL), while other strongly electron 
withdrawing cyano 14h and nitro 14i substituents maintained activity but reduced selectivity. 
We previously showed that treatment of a S. aureus promoter-lux array with HMPC 1 
produces a unique luminescence profile (suggesting a unique mechanism of action), but some 
similarities to DNA-damaging agents and/or DNA replication inhibitors were noted.
11
 This 
led to speculation that the anti-MRSA and apparent general cytotoxicity of 1 might arise from 
DNA binding. However, UV/vis experiments measuring the binding of 1 to calf thymus DNA 
and zone of growth inhibition disk measurements performed with 1 in the presence/absence 
of calf thymus or S. aureus genomic DNA appeared to rule this out. Nevertheless, the similar 
levels of HKC-8 toxicity observed in the current study with the majority of analogs of 1, 
combined with the absolute requirement of a carbodithioate function for anti-MRSA activity, 
led us to examine more closely whether 1 (and hence the class) may exert effects through 
non-specific nucleic acid and/or protein reactivity. 
The DNA-reactivity of 1 was probed by electrospray ionization mass spectrometry 
(ESI-MS) using a panel of single stranded, double stranded and G-quadruplex DNA 
oligonucleotides.  When incubated with up to 10-fold excesses of HMPC 1 under a variety of 
conditions, no evidence for any DNA:1 adducts was observed (Supporting Information 
Figure S1). Similarly, no adducts were observed by ESI-MS when 1 was incubated with RNA 
oligonucleotides (data not shown). 
The effects of HMPC 1 on DNA replication in vitro were explored next. In this assay, 
all of the enzymes, ancillary proteins, nucleotide precursors, DNA template and other 
molecular components required for duplication of circular bacterial DNA are present and able 
to effect replication in a cell-free environment.
16
 Covalent reactivity with any of the reaction 
components would be expected to read out as inhibition of replication. However, only slight 
inhibition of replication was observed with 1 at concentrations > 160 µM, well above its MIC 
against MRSA (Supporting Information Figure S2). In vitro RNA transcription assays 
similarly showed no inhibition by 1 at relevant concentrations (data not shown). The absence 
of effects for 1 in these assays rules out non-specific nucleic acid or protein reactivity as a 
contributor to the anti-MRSA mechanism of the pyrazole-4-carbodithioate class. 
In summary, pyrazole-4-carbodithioates are a new class of anti-MRSA agents that 
require the 4-carbodithioate function for activity. Non-specific covalent reactivity appears not 
to be part of the mechanism but intrinsic reactivity of the 4-carbodithioate may still play a 
role. We showed previously that MgrA-mediated defense responses are triggered by 1.
11
 
MgrA is an oxidation-sensing mechanism used by MRSA to counter challenges of reactive 
oxygen and nitrogen species. Upon detecting these species, a unique cysteine residue (Cys12) 
located at the dimer interface of the protein is oxidized to cysteine sulfenic acid, causing 
dissociation of MgrA from DNA and initiation of signalling pathways that turn on antibiotic 
resistance.
17
 We speculate that intracellular redox reactivity of the 4-carbodithioate function 
(aided by the neighboring OH group) triggers oxidative stress that leads to MgrA activation. 
Alternatively, metal chelation by the 4-carbodithioate and neighboring OH group may be 
involved.
18
 While limited selectivity (maximum 16-fold) for MRSA over eukaryotic HKC-8 
cells was achieved with the analogs explored here, further increases seem possible with a 
larger analog set. Studies to fully elucidate the anti-MRSA mechanism and identify the 
discrete intracellular targets using such selective analogs would undoubtedly prove insightful. 
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